Effect of tyrosine kinase inhibitors on Drosophila glioma model
Glioma are glia-derived primary brain tumors with very poor prognosis. The standard of care is surgery followed by radio- and chemo/immuno-therapy, or combinations thereof, however, all patients with glioma ultimately die. Thus, there is a need to test if recently approved drugs can inhibit the growth and progression of this tumor. We have developed a Drosophila glioma model based on the two genetic/ oncogenic pathways known to be most frequently activated in patients viz., the Ras/MAPK pathway and the PI3K pathway. Inhibitors of these two pathways do not help to limit the progression of glioma. Therefore, it is thought that other oncogenic pathways induce glioma growth and progression. We designed a chemical screen involving drugs targeting Tyrosine kinases (Selleck Biochem Chemical library) – key enzymes that are activated by oncogenic pathways. The chemical screen involves feeding glioma containing larvae 10uM and 300uM drugs from the library at early third instar stage, then allow these larvae to grow and mature to the third instar stage (120h of development), and then dissect the brain to study effects on glioma growth and track survival on days 5-7 when other glioma positive larvae die. Here, we present our progress from this screen focusing on chemicals A2-A11.
Primary Advisor's Department
Stander Symposium poster
"Effect of tyrosine kinase inhibitors on Drosophila glioma model" (2018). Stander Symposium Posters. 1285.